Advanced in Charcot-Marie-Tooth Disease

Alexander P. Grimm

Hoppe Seyler Str. 3, 
Tuebingen, BW, DE 
Advanced in Charcot-Marie-Tooth Disease
Hoppe Seyler Str. 3, 
Tuebingen, BW, DE 
OverviewLocationsClinical Research

Overview

Alexander Grimm practices in Tuebingen, Germany. Mr. Grimm is rated as an Advanced expert by MediFind in the treatment of Charcot-Marie-Tooth Disease. His top areas of expertise are Chronic Inflammatory Demyelinating Polyneuropathy, Cramp-Fasciculation Syndrome, Radial Nerve Dysfunction, and Guillain-Barre Syndrome.

His clinical research consists of co-authoring 123 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 7 articles and participated in 1 clinical trial in the study of Charcot-Marie-Tooth Disease.

Gender
Male

Locations

Hoppe Seyler Str. 3, Tuebingen, BW 72076, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Genetic Screening of an At-risk Population for Hereditary TransthyRetin-related AMyloidosis and Longitudinal Monitoring of TTR Positive Subjects- A Multicenter Epidemiological Longitudinal Protocol
Genetic Screening of an At-risk Population for Hereditary TransthyRetin-related AMyloidosis and Longitudinal Monitoring of TTR Positive Subjects- A Multicenter Epidemiological Longitudinal Protocol
Enrollment Status: Completed
Publish Date: June 29, 2025
A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A)
A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A)
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2024
Intervention Type: Drug
Study Drug: (RS)-Baclofen, Naltrexone Hydrochloride and D-Sorbitol
Study Phase: Phase 3
View 1 Less Clinical Trial

123 Total Publications

Distinct Epitopes Are Associated With Clinical Phenotypes in Autoimmune Nodopathies With Anti-Contactin1 Autoantibodies.
Distinct Epitopes Are Associated With Clinical Phenotypes in Autoimmune Nodopathies With Anti-Contactin1 Autoantibodies.
Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: November 17, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Grimm's expertise for a condition
ConditionClose
    View All 18 Advanced Conditions
    View All 49 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile